ThromboGenics, Novartis Win EU OK for Jetrea Eye Drug

ThromboGenics NV won the backing of European Union regulators for the Jetrea eye drug, moving the Belgian company closer to earning a payment of 90 million euros ($120 million) from its partner Novartis AG.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.